On April 3, Sinopharm Group China Biotechnology announced that its second-generation recombinant protein new crown vaccine has obtained the clinical trial approval document issued by the State Drug Administration. The vaccine was developed by Sinopharm Zhongsheng Biotechnology Research Institute/National Engineering Research Center for New Vaccines (referred to as “China Biological Research Institute”) and has independent intellectual property rights.
China Bio has already approved two inactivated vaccines in China, and according to China Bio, the second-generation recombinant new crown vaccine (NVSI-06-08) is a Chinese Based on the self-established computational structure vaccinology technology platform, the Institute of Biological Studies, on the basis of the first-generation recombinant new crown vaccine (NVSI-06-07), conducts computational analysis of the evolutionary laws and immune escape capabilities of the mutation sites of epidemic strains. The second-generation broad-spectrum COVID-19 vaccine designed and developed (mutation-integrated trimerized RBD).
At the end of 2021, Sinopharm Group China Biotechnology has coordinated the research and development institution China Institute of Biological Products and the production enterprises Lanzhou Institute of Biological Products and Beijing Institute of Biological Products to complete the technology transfer. . Lanzhou Institute of Biological Products and Beijing Institute of Biological Products have built GMP production workshops with continuous production capacity. At present, the production of 80 million doses has been completed, and the overseas supply exceeds 20 million doses. The production capacity can meet domestic and foreign demand.